Drugs / CTA101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04227015 | Jan 2020 → Jan 2022 overdue | acute lymphoblastic leukemia | He Huang | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT04154709 | Dec 2019 → Nov 2021 | acute lymphoblastic leukemia | Kai Lin Xu; Jun Nian Zheng | Unknown | No outcome recorded |
| Phase 1 | NCT04026100 | Dec 2019 → Aug 2022 | diffuse large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTA101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04026100 ↗ |
| Modality | Cell therapy | “Universal CD19-directed CAR-T cells” NCT04026100 ↗ |
| Route | Intravenous | “single infusion intravenously” NCT04026100 ↗ |
| Target | CD19 | “CD19-directed CAR-T cells” NCT04026100 ↗ |